Shorter TB Treatments Prove Cost-Effective in New Study
A recent economic evaluation published in the Indian Journal of Medical Research has unveiled that innovative, six-month all-oral treatment regimens for multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) are not only cost-effective but also result in better health outcomes when compared to traditional longer treatments in India.
This comprehensive study, conducted by the ICMR–National Institute for Research in Tuberculosis (ICMR-NIRT), made a detailed assessment of the cost-effectiveness of two bedaquiline-based regimens, namely BPaL (which includes bedaquiline, pretomanid, and linezolid) and BPaLM (which incorporates moxifloxacin). Both of these were analyzed against the existing treatment options that are part of the National TB Elimination Programme (NTEP), including shorter (9-11 months) and longer (18-20 months) regimens that also contain bedaquiline.
Economic Benefits of Shorter Regimens
The analysis highlighted that the BPaL regimen demonstrates superior effectiveness while also being a cost-saving alternative. Specifically, it was found that for every additional Quality Adjusted Life Year (QALY) gained, the healthcare system only spends INR 379 less per patient compared to standard treatment options. This indicates that not only does BPaL lead to better health outcomes, but it does so at a reduced financial burden.
Similarly, the BPaLM regimen exhibits high cost-effectiveness, requiring merely an extra INR 37 per patient for each additional QALY gained over standard treatment methods. Both regimens also incurred lower overall healthcare costs, which encompassed expenditures on medicines, medical visits, and follow-up care.
Improving Treatment Compliance
Treating MDR/RR-TB is notoriously challenging due to prolonged treatment durations, side effects, and increased costs. Switching to shorter all-oral regimens could significantly enhance treatment adherence among patients, diminish associated morbidities, and facilitate a quicker return to normal activities. This shift would also alleviate strain on the healthcare system.
The findings from this evaluation serve as crucial economic evidence supporting the incorporation of these shorter regimens into the management strategies for MDR/RR-TB within India. By condensing treatment durations from 9-18 months or more down to just six months, these regimens align with national health priorities aimed at optimizing resource use and expediting progress toward tuberculosis elimination.
Potential for Nationwide Adoption
In conclusion, the research posits that BPaL-based regimens may either save costs or represent highly cost-effective solutions, warranting their consideration for broader adoption under the NTEP. These findings mark a significant step towards enhancing India’s response to the challenges posed by drug-resistant tuberculosis. For those interested, the full study is accessible at the Indian Journal of Medical Research website.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
